Nitrosamine Risk Reviews: What to Request From an API Supplier

The supplier request, in one table

Quality and regulatory teams assessing commercial drug products cannot accept a supplier's one-page "nitrosamine-free" declaration as a defensible risk evaluation. Under current health authority expectations—including the U.S. Food and Drug Administration (FDA) Revision 2 guidance issued in September 2024, the European Medicines Agency (EMA) questions-and-answers document EMA/409815/2020 at Revision 23, and Health Canada's May 2026 nitrosamines policy—the marketing authorisation holder or finished drug product manufacturer bears ultimate regulatory accountability for patient safety. A receiving sponsor's risk evaluation is only as rigorous as the technical chemistry, process provenance, and analytical evidence furnished by its active pharmaceutical ingredient (API) manufacturers and intermediate vendors.

The workable file is version-controlled and has five parts. (1) A structured risk-evaluation report that answers all 15 risk factors in Question 4 of EMA/409815/2020, with a justification for every Yes, No, or not applicable. The APIC Revision 4 template (January 2026) and the CMDh questionnaire are accepted formats. FDA Revision 2 does not prescribe that form. It does expect the drug-product risk assessment to be built with the API manufacturer and to cover the root causes in Section III. (2) Chemistry disclosures for nitrosating agents and for nitrosatable secondary and tertiary amines, including amide solvents and quaternary ammonium residues. (3) The list of potentially present nitrosamines, the acceptable-intake basis attributed to the agency that set it, and the test results that support the conclusion. (4) A statement on virgin versus recovered solvents, reagents, and catalysts, including whether recovery is outsourced. (5) A written commitment to re-evaluate and tell the customer when the process, starting materials, or suppliers change. That commitment is a template and quality-agreement practice. It is not created by 21 CFR 314.70 or the EU variations regulation. Those rules govern what the application holder reports to the authority after a change.

The decision framework below outlines how receiving quality organizations should evaluate an API supplier's nitrosamine dossier, verify whether confirmatory testing is required, and manage ongoing lifecycle surveillance.

flowchart TD
    A["Supplier inquiry issued"] --> B{"Is the report structured?"}
    B -->|"One-page negative statement"| C["Ask again for all 15 EMA Q4 factors, each justified"]
    B -->|"Fifteen factors answered"| D{"Is a formation pathway plausible?"}
    C --> B
    D -->|"No pathway, and each No or NA is justified"| F["Step 1 can close without confirmatory testing"]
    D -->|"Justification missing"| G["Ask for the missing chemistry or process evidence"]
    G --> D
    D -->|"Pathway identified"| H["Step 2, unless a no-formation study is already documented"]
    H --> I["FDA recommendation: three U.S. batches across expiry, including the end of expiry"]
    I --> J{"Result versus that agency's acceptable intake"}
    J -->|"At or below 10 percent of the intake"| K["Negligible-risk record; a specification may be omitted"]
    J -->|"Above 10 percent and within the intake"| L["Add a release and stability control"]
    J -->|"Above the intake"| M["Mitigate, then use that agency's reporting path"]
    F --> N["Date the file and reopen it when a limit, process, or supplier changes"]
    K --> N
    L --> N
    M --> N

Why a one-page 'nitrosamine-free' statement fails Step 1

The 2018 finding of N-nitrosodimethylamine (NDMA) in valsartan led FDA, EMA, and other authorities to a three-step framework: risk evaluation, confirmatory testing when a risk is identified, and changes to the marketing authorisation plus corrective and preventive action. The original call-for-review submission dates have passed in the United States and the European Union. The need to keep the evaluation current has not. In the EU, marketing authorisation holders remain responsible for product quality under the Article 5(3) follow-up, and EMA/409815/2020 tells them to revisit the evaluation when new risk-factor or limit information appears. In the United States, Revision 2 is guidance, not a statute. Impurity control is still part of current good manufacturing practice, and FDA's recommended date for concluding NDSRI confirmatory testing and application changes (August 1, 2025) has passed.

In practice, pharmaceutical quality teams frequently encounter API vendors who respond to comprehensive nitrosamine questionnaires with a standardized, one-page declaration. These generic certificates typically assert that nitrosamines are not intentionally added during synthesis, that raw materials are procured from qualified vendors, and that the resulting active substance is compliant with general pharmacopeial purity standards. As documented in technical exchanges on the USP Nitrosamines Exchange, receiving drug product sponsors find these superficial statements practically useless during regulatory audits and pre-approval inspections (PAIs).

A one-line statement that nitrosamines are not added, or are not expected, does not answer the risk evaluation. FDA Revision 2 says the drug-product assessment should be done with the API manufacturer so the route of synthesis and the process conditions that create risk are known. The record that holds up is the chemistry and the controls, not a signature under a negative sentence.

Furthermore, the scope of risk assessments expanded dramatically with the recognition of Nitrosamine Drug Substance-Related Impurities (NDSRIs). Unlike small-molecule volatile nitrosamines such as NDMA or N-nitrosodiethylamine (NDEA)—which typically arise from solvent degradation or contaminated reagents—NDSRIs form when the active pharmaceutical ingredient itself, or one of its synthetic intermediates, possesses a vulnerable secondary or tertiary amine moiety that reacts with trace nitrites present in excipients or water. A legacy supplier certificate dating from 2020 or 2021 that evaluated only small-molecule nitrosamines fails current regulatory standards because it omits the API's own chemical susceptibility to nitrosation.

The 15 risk factors your request must cover

Quality groups usually ask for a structured report rather than a free-text letter. The APIC template, Report on the Risk of Potential Presence of Nitrosamine Impurities, Revision 4 (Version 4.1, January 2026), follows the 15 factors in Question 4 of EMA/409815/2020. It is an industry format, not a U.S. legal requirement. Another structure can still be acceptable if every factor is answered and justified. FDA's own root-cause discussion sits in Revision 2, Section III, and it is not numbered as these 15 questions.

A compliant supplier response must address all 15 factors individually, requiring the API manufacturer to designate each item as "Yes," "No," or "Not Applicable," accompanied by documented scientific rationale. The 15 factors span three operational domains: chemical synthesis of the drug substance, downstream drug product-relevant chemistry, and general good manufacturing practice (GMP) facility controls.

When reviewing an APIC Table 1 submission, quality units must verify that the supplier has not inserted blanket dismissals. For example, if Factor Q4.1 is checked "No," the justification must specifically identify every reagent used across the complete synthetic sequence and confirm the absence of nitrites, nitrates, and nitrous acid. If Factor Q4.8 indicates that the API is a secondary amine, the supplier cannot claim "No Risk" for the finished drug product; instead, the supplier must classify the drug substance as a vulnerable amine, provide pKa data, and furnish the drug product manufacturer with the exact chemical inputs required to model NDSRI formation in the finished dosage form.

Chemistry asks: nitrosating agents, vulnerable amines, recovered materials

Understanding nitrosamine risk requires rigorous organic chemistry analysis. Nitrosamines form through the electrophilic reaction of an active nitrosating agent with a vulnerable amine species. In pharmaceutical manufacturing environments, this reaction typically occurs in liquid solution under acidic, neutral, or even weakly basic conditions, depending on the presence of catalytic species and the pKa of the amine.

To conduct a thorough risk evaluation, quality teams must request detailed disclosures regarding two critical chemical categories: nitrosating agents (APIC Table 3) and vulnerable nitrosatable substances (APIC Table 4).

Nitrosating Agents and Upstream Sources

The primary nitrosating agent in synthetic chemistry is nitrous acid (HNO2), generated in situ by the acidification of inorganic nitrite salts (such as sodium nitrite, NaNO2). However, quality reviewers must look beyond intentional diazotization reactions. Other potent nitrosating agents frequently present in synthetic processes include:

• Nitrogen oxides (NO and NO2), which can be present as dissolved gaseous contaminants in nitric acid (HNO3) or formed during oxidation reactions.

• Alkyl nitrites (such as tert-butyl nitrite or isoamyl nitrite), widely utilized in organic synthesis for mild diazotization and functional group interconversions.

• Nitrosyl halides (NOCl, NOBr), formed when nitrites react with halide salts in acidic media, representing exceptionally reactive nitrosating electrophiles.

• Azide decomposition quenching byproducts: In tetrazole synthesis (common in sartan drug substances), excess sodium azide is frequently quenched with sodium nitrite under acidic conditions. If secondary amine solvents are present during this quench, nitrosamine formation is virtually instantaneous.

Vulnerable Amines and Amide Solvent Degradation

Secondary amines (e.g., dimethylamine, diethylamine, diisopropylamine) represent the most vulnerable substrate class because their reaction with nitrosating agents yields stable, highly carcinogenic N-nitrosodialkylamines without requiring an elimination step. Tertiary amines can also undergo dealkylative nitrosation under elevated temperatures or in the presence of reactive nitrosating electrophiles, yielding secondary amines that immediately react to form nitrosamines.

A major source of secondary amine contamination in API manufacturing is the hydrolytic and thermal degradation of common dipolar aprotic amide solvents. Dimethylformamide (DMF) degrades into dimethylamine (DMA) and formic acid; dimethylacetamide (DMAc) degrades into DMA and acetic acid; and N-methyl-2-pyrrolidone (NMP) degrades into 4-(methylamino)butyric acid. When DMF is heated in the presence of trace moisture or residual acid, significant quantities of volatile dimethylamine are liberated. If the synthetic route involves nitric acid, nitrous acid, or trace nitrites in any subsequent step, the generated DMA readily combines with nitrosonium ions to produce NDMA.

Recovered Solvents, Reagents, and Supply Chain Verification

FDA Revision 2, Section III.B.4, treats recovered solvents, reagents, and catalysts as a root cause. Residual amines can carry through recovery, and a quench that uses nitrous acid to destroy residual azide can form nitrosamines in the solvent being recovered. Outsourcing adds risk when the contractor is not told what is in the stream, or when shared equipment is cleaned without evidence that the impurities of concern are removed. The guidance illustrates the problem with recovered solvents and with a catalyst combined across customers. It does not rank warning letters or name a universal list of solvents.

In Revision 2 of its nitrosamines guidance, the FDA explicitly recommends that API manufacturers thoroughly audit their supply chains, establish rigorous monitoring programs for at-risk raw materials and intermediates, and directly verify with chemical vendors whether purchased materials are virgin or recovered. If a contract manufacturer utilizes an external solvent recovery facility, the sponsor must verify that the recovery vendor operates dedicated distillation equipment or maintains validated cleaning protocols between different client campaigns. Co-distilling solvent streams from unrelated chemical manufacturing lines has historically introduced trace secondary amines and nitrites into previously clean API production processes.

Test data: what to request and how to judge it

Analytical testing serves as the definitive empirical check on theoretical risk evaluations. However, testing alone cannot replace a comprehensive Step 1 evaluation; rather, confirmatory testing (Step 2) is triggered whenever a theoretical risk assessment identifies plausible formation pathways, precursor carry-over, or unverified supply chain inputs.

When requesting and reviewing analytical test data from an API supplier, quality units must enforce strict evidentiary standards regarding sample representation, batch numbers, analytical methodology, and detection limits.

Batch Sampling and Expiry Coverage

FDA Revision 2 recommends, rather than orders by statute, that confirmatory testing use at least three representative batches currently marketed in the United States, at time points within labeled expiry including the end of expiry, and that all available API sources be included. Freshly manufactured lots alone do not meet that recommendation. FDA also notes that high NDSRI levels have generally been associated with drug products rather than APIs, and that NDSRI levels can rise during storage. A data-driven argument that the structure will not form a nitrosamine, for example a targeted nitrosation study, can justify omitting confirmatory testing. Testing is not the default for every API.

Furthermore, if a drug product manufacturer utilizes multiple qualified API manufacturing sites or secondary suppliers, confirmatory testing must encompass representative lots from every approved source. Demonstrating that an API produced at Facility A is free of nitrosamines does not establish equivalence for the same chemical entity manufactured at Facility B, where water sources, solvent recovery practices, equipment trains, and raw material vendors inevitably differ.

FDA Per-Lot Testing Expectations

A point that is easy to drop out of a supplier file is how long incoming API testing continues. FDA Revision 2 expects the drug-product manufacturer to keep testing each API lot for nitrosamine impurities until it has verified that the supplier can consistently manufacture API within the recommended acceptable intake through the expiry or retest date. That is an expectation in guidance, tied to demonstrating control, not a sentence that testing of every lot is permanent once the demonstration exists.

Drug product quality teams cannot prematurely switch to skip-lot testing or reduce testing frequency based on initial qualification batches. Skip-lot testing or omission of an API release specification is only justified once process capability is statistically demonstrated across a sufficient historical production window (typically at least 10 consecutive commercial lots) and supported by long-term stability data.

Analytical Rigor: Method Validation, LOD, and LOQ

Control levels sit in the nanogram-per-day range, so the limit of quantitation has to be justified against the acceptable intake and the maximum daily dose. High-performance liquid chromatography with ultraviolet detection is usually not sensitive enough for that range. FDA expects a method commensurate with the level to be controlled. Liquid chromatography–tandem mass spectrometry and gas chromatography–tandem mass spectrometry are the usual choices. The guidance does not say that every file must use high-resolution mass spectrometry or multiple-reaction monitoring.

Quality teams must require suppliers to submit complete analytical validation packages conforming to ICH Q2(R2) guidelines. The validation report must disclose the Limit of Detection (LOD) and Limit of Quantitation (LOQ) for every target analyte. Crucially, the method LOQ must be low enough to quantify the impurity at or below the regulatory action threshold.

The 10 Percent-of-AI Threshold for Specification Omission

Regulatory authorities—including the FDA, EMA, Health Canada, and the World Health Organization (WHO)—converge on a harmonized action threshold regarding routine commercial release testing. If rigorous confirmatory testing across representative batches demonstrates that nitrosamine levels consistently remain at or below 10 percent of the established Acceptable Intake limit (or below a validated LOQ where the LOQ is demonstrated to be <= 10% of the AI), the sponsor is justified in omitting a routine release specification from the drug substance and drug product registrations.

If confirmatory results are above 10 percent of the recommended acceptable intake and still within it, FDA recommends a control in the release and stability specifications. For an approved application, that specification change is described as a changes-being-effected-in-30-days supplement. If results exceed the acceptable intake and a formulation, process, or packaging change is needed, major changes are submitted in a prior-approval supplement under 21 CFR 314.70(b) or 21 CFR 601.12(b). Exceeding the acceptable intake does not, by itself, mean every distributed batch is recalled. FDA's acceptable-intake page describes interim limits when a recall would disrupt supply, and Health Canada's May 29, 2026 update expects notification when a recall decision is made, not every time an elevated result is recorded.

Limits that moved after your last review

A common vulnerability in pharmaceutical compliance files is the assumption that an approved nitrosamine risk assessment remains permanently valid. In reality, the toxicological benchmarks and regulatory policies governing nitrosamines have evolved continuously throughout 2024, 2025, and 2026. A quality file established under 2022 guidelines is likely obsolete if it has not been systematically reconciled against recent health authority revisions.

Toxicological Architecture: ICH M7(R2) and the Cohort of Concern

Under the International Council for Harmonisation (ICH) guideline M7(R2), mutagenic impurities are generally managed using the Threshold of Toxicological Concern (TTC) of 1.5 micrograms per day (µg/day), which corresponds to a theoretical 1-in-100,000 excess lifetime cancer risk. However, N-nitroso compounds belong to the "cohort of concern"—a structural class of exceptionally potent alkylating mutagens for which the standard TTC is explicitly inapplicable.

Acceptable intakes are compound-specific because N-nitroso compounds sit in the ICH M7(R2) cohort of concern, so the 1.5 µg/day threshold of toxicological concern does not apply. Where robust rodent carcinogenicity data exist, the intake is derived from a TD50. On FDA's CDER Nitrosamine Impurity Acceptable Intake Limits page, Table 2 (compound-specific data or read-across) lists NDMA at 96 ng/day and NDEA at 26.5 ng/day. The page notes that the NDMA figure was previously communicated on September 3, 2020. Do not carry the older sartan interim set forward as if it were still the FDA table. On the same page, the CPCA table lists N-nitroso-N-methyl-4-aminobutyric acid (NMBA) at potency category 4, 1500 ng/day, and N-nitrosodiisopropylamine (NDIPA) at potency category 5, 1500 ng/day. EMA Appendix 1 and Health Canada Appendix 1 are separate lists and have been revised on their own dates, including Health Canada's revisions of NMBA and NDIPA noted on May 31, 2024. Cite the agency, the list, and the revision. One number labeled as harmonized for NMBA or NDIPA is not supportable from these sources.

The CPCA Framework for Complex NDSRIs

For NDSRIs that lack robust carcinogenicity data and a suitable read-across surrogate, FDA's RAIL guidance (final August 2023) and EMA Appendix 2 use the Carcinogenic Potency Categorization Approach. Both sort structures into five potency categories using features such as the alpha-hydrogen count and deactivating groups. The intake attached to category 1 is not the same in both regions. EMA Appendix 2 assigns category 1 an acceptable intake of 18 ng/day. FDA recommends 26.5 ng/day for category 1 for products intended for the United States, including when another region uses a different category 1 figure. Categories 2, 3, 4, and 5 are 100, 400, 1500, and 1500 ng/day in both the FDA RAIL table and EMA Appendix 2. Category 5 is the less potent structural case. It does not allow a higher intake than category 4.

The administrative deadlines set in 2020 and 2021 have passed. The file still has to move when the lists move. FDA recommended that NDSRI confirmatory testing be concluded and required application changes submitted by August 1, 2025, and that date has passed. Health Canada allows up to three years from August 1, 2025 (to August 1, 2028) for corrective and preventive action on acceptable intakes published in its Appendix 1 before that date, and up to three years from the publication date for limits published on or after August 1, 2025. EMA expects corrective and preventive action within three years of an acceptable intake being established and published. Those are not one shared clock.

A worked record: one API, one request file

The log below is a worked example for a model active substance that uses dimethylformamide in stage 2 and a secondary-amine coupling in stage 3. Every status, concentration, and limit of quantitation in the table is hypothetical. None of those figures is an agency limit or a result measured from a real supplier.

The Reviewer's Red-Flag Checklist

When a response comes back, six patterns should keep the file open:

• Blanket Negative Declarations: Any document stating simply that 'the product is free of nitrosamines' without answering the 15 individual risk factors.

• Unsubstantiated 'Not Applicable' Designations: Marking solvent recovery or equipment cleaning as 'NA' when the facility operates shared multi-product synthesis lines.

• Lack of LOQ / LOD Disclosure: Analytical test reports that state 'None Detected' but fail to specify the method's Limit of Quantitation or provide chromatograms.

• Testing only fresh batches: Release data on three newly made lots, with no result at or near the end of labeled expiry. FDA's recommendation in Revision 2 is three representative U.S. batches across expiry, including the end of expiry.

• Undefined Solvent Recovery Streams: Stating that solvents are 'recycled in accordance with GMP' without verifying whether recovery is performed on dedicated internal equipment or outsourced to commercial recyclers.

• No change commitment: A static assessment with no sentence, in the report or the quality agreement, that the supplier will re-evaluate and notify the customer when the process, materials, or suppliers change.

Managing Recalcitrant Suppliers: The APIC May 2025 Playbook

In scenarios where an API vendor refuses to provide detailed synthetic information citing proprietary intellectual property, quality units must follow the escalation pathway established in APIC's "Nitrosamines Risk Management: Guidance for API Manufacturers" (May 2025). Sponsors cannot simply drop the inquiry. Instead, the drug product manufacturer must: (1) utilize the Drug Master File (DMF) or Certificate of Suitability (CEP) Letter of Authorization mechanism to request that health authorities inspect the confidential synthesis during application review; (2) execute an internal, worst-case risk evaluation assuming maximum potential carry-over of vulnerable amines; and (3) perform rigorous end-product confirmatory testing across all commercial batches to establish empirical safety.

Change notification: keeping the review alive

A nitrosamine risk evaluation is not a one-time regulatory filing; it is an active lifecycle control document. A risk profile that was thoroughly documented and approved in 2024 can be instantly invalidated by an unannounced process change at an API manufacturing site or raw material vendor.

Section 8 of the APIC Revision 4 template is the sentence to ask the supplier to adopt: if the process, starting materials, or suppliers change in a way that can affect the evaluation, the manufacturer will reassess, revise the report when needed, and inform customers of a change in the outcome. That sentence becomes an obligation only if the quality agreement or supply contract incorporates it. It is not a regulation. Once the customer implements a responsive change, the application holder uses the U.S. supplement rules or the EU variations framework to tell the authority what the application requires.

• The synthetic route of the active substance, including changes in reaction sequence, reagents, catalysts, or reaction stoichiometry.

• The sources, manufacturing processes, or specifications of Key Starting Materials (KSMs) and advanced intermediates.

• The specifications, grades, or suppliers of process solvents, particularly dipolar aprotic solvents (DMF, DMAc, NMP) subject to degradation.

• Solvent recovery operations, including any transition from internal dedicated recovery to third-party commercial recycling vendors.

• Manufacturing equipment trains, dedicated versus shared equipment status, or cleaning validation protocols.

• Manufacturing site or facility relocation, including secondary synthesis sites or intermediate processing contractors.

The Confidentiality Interface: DMF Letters of Authorization

When an API supplier operates under a Type II Drug Master File (in the United States) or an Active Substance Master File / CEP (in Europe), the vendor typically maintains the specific route of synthesis and intermediate reaction conditions within the restricted, proprietary portion of the file. Receiving sponsors receive only an open-part applicant's summary and a Letter of Authorization (LoA) granting regulators permission to review the closed dossier.

Quality teams must recognize that relying solely on a DMF Letter of Authorization creates severe compliance vulnerabilities if not paired with a robust bilateral quality agreement. While the FDA or EMA will inspect the closed DMF during initial application review, regulatory agencies do not actively notify drug product sponsors when an API vendor submits minor annual updates or manufacturing modifications to a Type II DMF. Sponsors seeking to prevent post-approval supply interruptions should consult the operational strategies outlined in our analysis of API supplier DMF letters of authorization and notification traps, which details how unannounced Type II DMF amendments routinely trigger inspection findings and import alerts.

In a CDMO contract, nitrosamine surveillance belongs in the audit rights, the cleaning limits, and the path for a batch that fails those limits. Ambiguous raw-material and change-control language is a known inspection problem in quality agreements. It is not, on this record, something that can be ranked as the most frequent cause of warning letters.

Retrigger Discipline: Maintaining the Live Dossier

To ensure that commercial dossiers remain permanently inspection-ready, drug product quality units must establish an internal standard operating procedure governing nitrosamine retrigger events. A formal re-evaluation of the supplier risk file must be automatically initiated whenever any of the following triggers occur:

• Health Authority AI Revisions: A regulatory agency (FDA, EMA, Health Canada, or WHO) publishes a new or lowered Acceptable Intake limit for an impurity relevant to the drug substance.

• Supplier Process Change: Receipt of a formal change-control notification from the API vendor detailing synthetic route, solvent, or facility adjustments.

• Annual product review: Re-read raw-material trends, stability results, and incoming API release data at the product review the quality system already runs.

• OOS or Out-of-Trend (OOT) Investigation: Any analytical observation of unexpected chromatographic peaks or unexplained degradation during commercial release or stability testing.

• New Scientific Literature: Peer-reviewed publications or regulatory alerts identifying novel degradation pathways or catalytic formation mechanisms applicable to the therapeutic class.

A version-controlled request file, a 15-factor evaluation, and a written change commitment in the quality agreement keep the review alive after the original call-for-review dates.

Sources

This analysis is based on primary regulatory guidance documents, international standards, and official technical templates governing pharmaceutical impurity control:

• U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research: Control of Nitrosamine Impurities in Human Drugs: Guidance for Industry (Revision 2, September 2024; Effective September 5, 2024). https://www.fda.gov/media/141720/download

• U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research: CDER Nitrosamine Impurity Acceptable Intake Limits (webpage, content current as of August 6, 2026). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cder-nitrosamine-impurity-acceptable-intake-limits

• European Medicines Agency (EMA): Nitrosamine impurities: guidance for marketing authorisation holders, including Questions and Answers for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products (EMA/409815/2020 Rev. 23, October 10, 2025; and Appendix 1 Acceptable Intakes EMA/42261/2025 Rev. 13, June 24, 2026). https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/pharmacovigilance-post-authorisation/referral-procedures-human-medicines/nitrosamine-impurities/nitrosamine-impurities-guidance-marketing-authorisation-holders

• Heads of Medicines Agencies / Co-ordination Group for Mutual Recognition and Decentralised Procedures - Human (CMDh): Nitrosamine impurities technical guidance and response templates. https://www.hma.eu/human-medicines/cmdh/nitrosamine-impurities.html

• Active Pharmaceutical Ingredients Committee (APIC / CEFIC): Report on the Risk of Potential Presence of Nitrosamine Impurities, Supplier Template Revision 4 (January 2026, Version 4.1). https://apic.cefic.org/wp-content/uploads/2026/03/APIC_Template_for_report_on_Nitrosamine_Risk_Evaluation_Update-January-2026_V4-1.pdf

• Active Pharmaceutical Ingredients Committee (APIC / CEFIC): Nitrosamines Risk Management: Guidance for API Manufacturers (Final, May 2025). https://apic.cefic.org/wp-content/uploads/2025/05/APIC-Nitrosamines-Risk-management_Guidance-for-API-Manufacturers_Final-1.pdf

• Health Canada: Nitrosamine impurities in medications: Overview (What's new, including guidance updates of August 1, 2025, and May 29, 2026, with Appendix 1 Acceptable Intake table updates). https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/information-health-product/drugs/nitrosamine-impurities.html

• World Health Organization (WHO): WHO good practice considerations for the prevention and control of nitrosamines in pharmaceutical products (Annex 2). https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/production/annex-2_who-good-practice-considerations-for-the-prevention-and-control-of-nitrosamines-in-pharmaceutical-products.pdf

• International Council for Harmonisation (ICH): ICH Harmonised Guideline M7(R2): Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk (Step 4, 2023). https://database.ich.org/sites/default/files/ICH_M7(R2)_Guideline_Step4_2023_0216_0.pdf

• USP Nitrosamines Exchange: Technical practitioner discussions regarding API supplier risk evaluation responses and regulatory expectations. https://nitrosamines.usp.org/t/whats-your-experience-on-api-risk-assessments/4241